APOE ε4 与脑动静脉畸形患者的脑出血
这项横断面研究分发现与复制两阶段,使用 UK Biobank 与 All of Us 研究项目的个体数据,评估已知脑动静脉畸形患者中 APOE ε4 与脑出血风险的关联。发现阶段 253 例中 63 例(24.9%)发生脑出血,在 240 例欧洲血统者的多因素分析中 APOE ε4 与脑出血风险升高相关(OR 4.58;95%CI 2.13-10.34;P < .001)。复制阶段 159 例中 29 例(18.2%)发生脑出血,在 101 例欧洲血统者的多因素分析中同样相关(OR 4.52;95%CI 1.18-19.38;P = .03)。作者认为 APOE ε4 信息可能有助于识别脑动静脉畸形患者中的脑出血高危者,并建议评估脑淀粉样血管病作为该关联的可能中介机制。
要点
- 在 UK Biobank 已知脑动静脉畸形患者 240 例欧洲血统者的多因素分析中,APOE ε4 与脑出血风险升高相关(OR 4.58;95%CI 2.13-10.34;P < .001)。
- 在 All of Us 已知脑动静脉畸形患者 101 例欧洲血统者的多因素分析中,APOE ε4 与脑出血风险升高相关(OR 4.52;95%CI 1.18-19.38;P = .03)。
- 发现阶段 253 例已知脑动静脉畸形患者中 63 例(24.9%)发生脑出血;复制阶段 159 例中 29 例(18.2%)发生脑出血。
- 作者认为 APOE ε4 状态信息可能有助于识别脑动静脉畸形患者中脑出血风险特别高者。
- 作者建议评估脑淀粉样血管病作为所观察到关联的可能中介机制。
适用人群与场景
- UK Biobank 中已知脑动静脉畸形的参与者 253 例(发现阶段;平均[SD]年龄 56.6[8.0]岁,女性 119 例[47.0%])。
- All of Us 研究项目中已知脑动静脉畸形的参与者 159 例(复制阶段;平均[SD]年龄 57.1[15.9]岁,女性 106 例[66.7%])。
- 多因素分析人群为欧洲血统者:发现阶段 240 例,复制阶段 101 例。
诊断标准与关键阈值
- 脑动静脉畸形与脑出血的发生在入组时通过经验证的国际疾病分类第九版和第十版编码确认。
- APOE 变异 rs429358 和 rs7412 的基因型数据用于确定 ε 状态。
研究设计与关键结果
- 研究类型:横断面研究,分发现与复制两阶段,使用 UK Biobank(2012年3月发布,2023年10月最后更新)与 All of Us 研究项目(2018年5月6日启动,最新更新于2023年10月)的个体水平数据,共 412 例参与者。
- 发现阶段:253 例已知脑动静脉畸形患者中 63 例(24.9%)发生脑出血;在 240 例欧洲血统者的多因素 logistic 回归中,APOE ε4 与脑出血风险升高相关(OR 4.58;95%CI 2.13-10.34;P < .001)。
- 复制阶段:159 例已知脑动静脉畸形患者中 29 例(18.2%)发生脑出血;在 101 例欧洲血统者的多因素分析中,APOE ε4 与脑出血风险升高相关(OR 4.52;95%CI 1.18-19.38;P = .03)。
证据类型、等级与局限
- 证据类型:横断面研究,分发现与复制两阶段。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,APOE ε4 状态信息可能有助于识别脑动静脉畸形患者中脑出血风险特别高者。
- 作者建议将脑淀粉样血管病作为所观察到关联的可能中介机制进行评估。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Intracerebral hemorrhage (ICH) is a serious complication of brain arteriovenous malformation (AVM). Apolipoprotein E (APOE) ε4 is a well-known genetic risk factor for ICH among persons without AVM, and cerebral amyloid angiopathy is a vasculopathy frequently observed in APOE ε4 carriers that may increase the risk of ICH.
OBJECTIVE: To assess whether APOE ε4 is associated with a higher risk of ICH in patients with a known AVM.
DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional study including 412 participants was conducted in 2 stages (discovery and replication) using individual-level data from the UK Biobank (released March 2012 and last updated October 2023) and the All of Us Research Program (commenced on May 6, 2018, with its latest update provided in October 2023). The occurrence of AVM and ICH was ascertained at the time of enrollment using validated International Classification of Diseases, Ninth Revision and Tenth Revision, codes. Genotypic data on the APOE variants rs429358 and rs7412 were used to ascertain the ε status.
MAIN OUTCOMES AND MEASURES: For each study, the association between APOE ε4 variants and ICH risk was assessed among patients with a known AVM by using multivariable logistic regression.
RESULTS: The discovery phase included 253 UK Biobank participants with known AVM (mean [SD] age, 56.6 [8.0] years, 119 [47.0%] female), of whom 63 (24.9%) sustained an ICH. In the multivariable analysis of 240 participants of European ancestry, APOE ε4 was associated with a higher risk of ICH (odds ratio, 4.58; 95% CI, 2.13-10.34; P < .001). The replication phase included 159 participants with known AVM enrolled in All of Us (mean [SD] age, 57.1 [15.9] years; 106 [66.7%] female), of whom 29 (18.2%) sustained an ICH. In multivariable analysis of 101 participants of European ancestry, APOE ε4 was associated with higher risk of ICH (odds ratio, 4.52; 95% CI, 1.18-19.38; P = .03).
CONCLUSIONS AND RELEVANCE: The results of this cross-sectional study of patients from the UK Biobank and All of Us suggest that information on APOE ε4 status may help identify patients with brain AVM who are at particularly high risk of ICH and that cerebral amyloid angiopathy should be evaluated as a possible mediating mechanism of the observed association.
参考来源
- Renedo D, Rivier CA, Koo AB, et al. APOE ε4 and Intracerebral Hemorrhage in Patients With Brain Arteriovenous Malformation. JAMA Netw Open. 2024. PMID: 38363572. doi:10.1001/jamanetworkopen.2023.55368
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。